This is the first in a series of NIDA Notes articles that will follow a team of researchers seeking a medication for methamphetamine addiction. This installment describes the early promise of the compound lobeline and the new directions the team discovered in studying it.
The finding from an 18-month-long clinical trial strengthens hope that pharmacotherapy can break nicotine’s especially tenacious hold on people with serious mental illness such as bipolar disorder or schizophrenia.
Methamphetamine use and HIV infection raise the risk for functional dependence, or the need for assistance with everyday tasks. People who use methamphetamine and are HIV positive showed the highest levels of functional dependence in most domains of daily life.
NIDA plans to provide $750 travel awards to 27 junior investigators to present their research on women or sex/gender differences in any area of drug abuse at the annual meeting of the College on Problems of Drug Dependence in Phoenix, Arizona, June 13–18, 2015. Deadline to apply is December 5, 2014.
Despite common concerns that encouraging patients to quit smoking might endanger their success in treatment of substance use and mood or anxiety disorders, smoking cessation appears unlikely to hinder and may even help recovery.
Dr. Kevin M. Gray discusses why it’s the perfect time for discovering new evidence-based treatments for marijuana dependence. In an accompanying podcast, he discusses a clinical trial that examines NAC’s potential as a treatment for marijuana dependence among adults.
Nano-antiretroviral therapy (nano-ART) turns macrophages—one of the very cell types that HIV uses to replicate and spread through the body—into carriers for anti-HIV medications. The approach has the potential to make treatment for HIV easier and more effective.